-

Phibro Animal Health Corporation Announces National Launch of Restoris™ Piezoelectric Dental Gel for Dogs

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and support long-term oral health in dogs with periodontal disease. Developed in collaboration with a leading U.S. dental school and licensed to Phibro, Restoris represents a breakthrough in veterinary dental care, offering a dual mechanism of action to restore oral health at its foundation.

The launch of Restoris builds on our recently announced license agreement for a novel therapeutic product targeting periodontal health in companion animals through a different mechanism of action. Together, these products form the foundation of a portfolio of assets in this exciting therapeutic area.

Periodontal disease is the most common clinical condition affecting adult dogs, with studies showing that 80–90% of dogs over the age of three have some component of periodontal disease. The disease is often invisible to pet owners, as it begins beneath the gumline and progresses silently until advanced stages. Untreated, periodontal disease can lead to chronic pain, infection, and tooth loss, and has been linked to systemic health problems including heart, kidney, and liver disease.

Restoris is applied directly into periodontal pockets using a prefilled syringe and then cured with supplied UV light. The gel’s piezoelectric particles generate microcurrents that stimulate bone-forming osteoblast cells, promoting new bone growth and reducing periodontal pocket depth. This innovative approach supports the natural healing response of periodontal tissues and helps restore healthy tooth attachment. Restoris has demonstrated efficacy in laboratory and clinical studies, showing significant reductions in periodontal pocket depth and generating alveolar bone around the affected tooth 30 days following treatment. This dual mechanism of action helps to re-establish periodontal integrity and support long-term oral health.

“We are excited to introduce Restoris to veterinarians and pet owners nationwide. At Phibro, our mission is to deliver innovative solutions that improve animal health and well-being. Restoris is a testament to our commitment to advancing veterinary medicine and supporting the lifelong health of companion animals,” said Jack C. Bendheim, Chairman, President, and Chief Executive Officer of Phibro Animal Health Corporation.

Restoris is now available for pre-order from Patterson Veterinary Supply and will ship within the next 30 days.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation (Nasdaq: PAHC) is a diversified global developer, manufacturer, and supplier of a broad range of animal health and mineral nutrition products. With a commitment to safe and effective solutions for our customers’ unique challenges, Phibro optimizes animal health and nutrition for better lives and a more sustainable world. Learn more at www.pahc.com.

Contacts

Media Contact: Phibro Animal Health Corporation
Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Blvd., Ste. 21
Teaneck, NJ 07666
+1 201-329-7300
investor.relations@pahc.com

Phibro Animal Health Corporation

NASDAQ:PAHC

Release Versions

Contacts

Media Contact: Phibro Animal Health Corporation
Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Blvd., Ste. 21
Teaneck, NJ 07666
+1 201-329-7300
investor.relations@pahc.com

More News From Phibro Animal Health Corporation

Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2025 and its updated financial guidance for the year ending June 30, 2026. Highlights for the three months ended September 30, 2025 (compared to the three months ended September 30, 2024) Net sales of $363.9 million, an increase of $103.5 million, or 40% Net income of $26.5 million, an increase of $19.6 million Di...

Phibro Animal Health Corporation Declares Quarterly Dividend

TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner w...

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (88...
Back to Newsroom